You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
誠達藥業(301201.SZ):受輝瑞原料藥工廠委託 為其定製研發醫藥中間體PF-07304814
格隆匯 02-15 19:39

格隆匯2月15日丨誠達藥業(301201.SZ)發佈股票交易異常波動公吿,公司注意到近期有投資者在媒體和互動易平台上對公司醫藥中間體業務十分關注,尤其是公司醫藥中間體是否用於輝瑞新冠病毒防治特效藥中。現就相關情況説明:

公司主要致力於為跨國製藥企業及醫藥研發機構提供關鍵醫藥中間體CDMO服務,受輝瑞原料藥工廠委託,為其定製研發醫藥中間體PF-07304814,對應的2020年、2021年1-6月銷售收入佔營業收入的比例分別為0.61%,1.16%,該部分銷售收入佔公司營業收入的比例較小,暫未對公司業績產生重大影響。公司暫未發現其他可能或已經對公司股票交易價格產生較大影響的的媒體報道及市場傳聞。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account